India embraces AI and Virtual Care to bridge workforce gaps in healthcare: Philips Future Health Index India 2024

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis

Sanofi invests €40 million to strengthen antibody bioproduction in France

Emcure Pharmaceuticals teams up with MS Dhoni to bat for stroke awareness

Emcure and Dhoni, through a video, urge everyone to be aware about symptoms of stroke and educate at least one person for identification of stroke and spread its awareness

AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US

This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr

Hospital business revenues increase 13.9% to Rs. 1,655 crore

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore